|کد مقاله||کد نشریه||سال انتشار||مقاله انگلیسی||ترجمه فارسی||نسخه تمام متن|
|5628661||1406384||2017||3 صفحه PDF||سفارش دهید||دانلود کنید|
- A systemic inflammatory response frequently coexists with status epilepticus, and therefore should be assessed routinely.
- The assessment of SIRS among SE patients, may contribute to more effective planning of treatment and outcome prediction.
- There is a link between the presence of SIRS and resistance to SE treatment.
ObjectivesThis study was aimed at identifying patients with systemic inflammatory response syndrome (SIRS) and determining whether the presence of SIRS on admission was associated with drug resistance and poor outcome in status epilepticus (SE) patients.MethodsWe conducted a prospective review of patients consecutively admitted to two territory centers over a 7-year period. SIRS was considered present if the necessary criteria persisted for 12Â h. Other potential outcome predictors in a cohort of patients with SE were also collected. The primary outcome was defined as mortality during 30 days of observation, and the secondary outcome was defined as refractory SE. Logistic regression was used to determine independent predictors.ResultsOf 127 subjects, 85 patients met the inclusion criteria. In the entire population, 43% developed SIRS at SE onset and, among them, 16% had SIRS attributed to SE alone. Subjects with refractory SE accounted for 39%, and the mortality rate for the entire population was 35%. SIRS was independently associated with drug resistance (OR 3.93, 95% CI: 1.57-9.9) and death (OR 6.76, 95% CI: 1.33-34.32).ConclusionsWe observed that approximately half of the patients with SE developed SIRS, and that SIRS is the independent risk factor for drug resistance and death. We also observed that SIRS was a secondary event for SE itself.
Journal: Epilepsy Research - Volume 137, November 2017, Pages 53-55